Onyx Studio Sessions: Fabian Gerlinghaus, Cellares
Can this man bring down the cost of some of the most expensive and hope-inspiring new therapies on the market?
Cell and Gene
From Grammys to Gene Therapy: Gaurav Shah’s Rocket-Fueled Revolution in Rare Diseases
A Grammy-winning CEO is taking gene therapy to new heights.
From paper to pancreas: how Aspect Biosystems is leading a bioprinting revolution
A recent multi-billion dollar deal with Novo Nordisk in diabetes and obesity, and an injection of significant funding through a $200 million government partnership - Aspect is worth watching as they enter 2025.
enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
Ocugen has a cure in sight
“The cost of gene therapies can reach millions of dollars per patient… Our goal is developing cost-effective treatments that can be accessible globally.”
Gene therapy in ophthalmology is on the cusp of a breakthrough
"One of our first patients was treated over five years ago. He had received 109 injections over 10 years, and five years after a single Ixo-Vec injection, he is free of injections with stable vision and no fluid in the eye."
CAR T-cell therapies beat blood cancer - can they do the same for autoimmune diseases?
CAR T-cell therapies are often lauded as one of the industry’s most important frontiers, and these therapies have seen amazing success in treating hematological cancers — will autoimmune diseases yield next?
Cell therapy used to be expensive, then Cellares changed everything
The CEO of Cellares sits down to tell us how the Cell Shuttle, an engineering marvel of 21st Century biotech, was invented and the lives that it could save...
How rationally designed therapeutics could revolutionize gene therapy
Gene therapy holds incredible promise, but the challenge has always been delivery - Affinia Therapeutics seeks to solve one of the most important problems that the industry faces.